Molecular insight into substrate recognition by human cytosolic sialidase NEU2

Proteins: Structure, Function and Bioinformatics

Volumn 80, Issue 4, 2012, Pages 1123-1132

  Mozzi, Alessandra ^a   Mazzacuva, Pietro ^a   Zampella, Giuseppe ^a   Forcella, Matilde Emma ^a   Fusi, Paola Alessandra ^a   Monti, Eugenio ^b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Active site; Ganglioside(s); Glycohydrolases; Molecular docking; Oligosaccharide(s); Sialic acid; Site directed mutagenesis

Indexed keywords

ANTIVIRUS AGENT; DISACCHARIDE; GANGLIOSIDE GM3; GLUCOSE; GLYCAN; HUMAN CYTOSOLIC SIALIDASE NEU2; LACTOSE; NUCLEOPHILE; OLIGOSACCHARIDE; SIALIC ACID; SIALIDASE; SIALYL LACTOSE; TRISACCHARIDE; UNCLASSIFIED DRUG;

ARTICLE; BINDING KINETICS; CATALYSIS; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; ENZYME SUBSTRATE; HUMAN; MOLECULAR DOCKING; MOLECULAR INTERACTION; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL;

CATALYTIC DOMAIN; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; CYTOSOL; ENZYME ACTIVATION; ENZYME ASSAYS; ESCHERICHIA COLI; GALACTOSE; HUMANS; HYMECROMONE; INFLUENZA A VIRUS, H1N1 SUBTYPE; LACTOSE; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; NEURAMINIDASE; PROTEIN BINDING; SIALIC ACIDS; SUBSTRATE SPECIFICITY;

MAMMALIA;

EID: 84857771364     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.24013     Document Type: Article

References (38)

1. Schauer R. Sialic acids: fascinating sugars in higher animals and man. Zoology (Jena) 2004; 107: 49-64.
2. Schauer R. Sialic acids as regulators of molecular and cellular interactions. Curr Opin Struct Biol 2009; 19: 507-514.
3. Saito M, Yu RK. Biochemistry and function of sialidases. In: Rosenberg A, editor. Biology of the sialic acids. New York: Plenum Press; 1995. pp 261-313.
4. Varghese JN, Colman PM. Three-dimensional structure of the neuraminidase of influenza virus A/Tokyo/3/67 at 2.2 A resolution. J Mol Biol 1991; 221: 473-486.
5. Taylor G. Sialidases: structures, biological significance and therapeutic potential. Curr Opin Struct Biol 1996; 6: 830-837.
6. Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet 2000; 355: 827-835.
7. Itzstein M, Thomson R. Anti-influenza drugs: the development of sialidase inhibitors. Handbook Exp Pharmacol 2009: 111-154.
8. Hata K, Koseki K, Yamaguchi K, Moriya S, Suzuki Y, Yingsakmongkon S, Hirai G, Sodeoka M, von Itzstein M, Miyagi T. Limited inhibitory effects of oseltamivir and zanamivir on human sialidases. Antimicrob Agents Chemother 2008; 52: 3484-3491.
9. Chavas LM, Kato R, Suzuki N, von Itzstein M, Mann MC, Thomson RJ, Dyason JC, McKimm-Breschkin J, Fusi P, Tringali C, Venerando B, Tettamanti G, Monti E, Wakatsuki S. Complexity in influenza virus targeted drug design: interaction with human sialidases. J Med Chem 2010; 53: 2998-3002.
10. Monti E, Bonten E, D'Azzo A, Bresciani R, Venerando B, Borsani G, Schauer R, Tettamanti G. Sialidases in vertebrates: a family of enzymes tailored for several cell functions. Adv Carbohydr Chem Biochem 2010; 64: 403-479.
11. Monti E, Preti A, Nesti C, Ballabio A, Borsani G. Expression of a novel human sialidase encoded by the NEU2 gene. Glycobiology 1999; 9: 1313-1321.
12. Tringali C, Papini N, Fusi P, Croci G, Borsani G, Preti A, Tortora P, Tettamanti G, Venerando B, Monti E. Properties of recombinant human cytosolic sialidase HsNEU2. The enzyme hydrolyzes monomerically dispersed GM1 ganglioside molecules. J Biol Chem 2004; 279: 3169-3179.
13. Chavas LM, Tringali C, Fusi P, Venerando B, Tettamanti G, Kato R, Monti E, Wakatsuki S. Crystal structure of the human cytosolic sialidase Neu2. Evidence for the dynamic nature of substrate recognition. J Biol Chem 2005; 280: 469-475.
14. Buschiazzo A, Amaya MF, Cremona ML, Frasch AC, Alzari PM. The crystal structure and mode of action of trans-sialidase, a key enzyme in Trypanosoma cruzi pathogenesis. Mol Cell 2002; 10: 757-768.
15. Burmeister WP, Henrissat B, Bosso C, Cusack S, Ruigrok RW. Influenza B virus neuraminidase can synthesize its own inhibitor. Structure 1993; 1: 19-26.
16. Sambrook J, Russell D. Molecular cloning: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2001. 2344 p.
17. MacKerell AD, Jr., Bashford D, Belott M, Dunbrack RL, Evanseck JD, Field MJ, Fischer S, Gao J, Guo H, Ha S, Joseph-McCarthy D, Kuchnir L, Kuczera K, Lau FTK, Mattos C, Michnick S, Ngo T, Nguyen DT, Prodhom B, Reiher WE, Roux B, Schlenkrich M, Smith JC, Stote R, Straub J, Watanabe M, Wiòrkiewicz-Kuczera J, Yin D, Karplus M. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B 1998; 102: 3586-3616.
18. Labute P. The generalized Born/volume integral implicit solvent model: estimation of the free energy of hydration using London dispersion instead of atomic surface area. J Comput Chem 2008; 29: 1693-1698.
19. Labute D. The London dG Scoring function for binding affinity estimation. Unpublished.
20. Sun R, Zheng H, Fang Z, Yao W. Rational design of aminoacyl-tRNA synthetase specific for p-acetyl-L-phenylalanine. Biochem Biophys Res Commun 2010; 391: 709-715.
21. Bertini R, Allegretti M, Moriconi A, Locati M, Zampella G., Cervellera MN, Di Cioccio V, Cesta MC, Galliera E, Martinez FO, Di Bitondo R, Troiani G, Sabbatini V, D'Anniballe G, Anacardio R, Cutrin JC, Cavalieri B, Mainero F, Strippoli R, Villa P, Di Girolamo M, Martin F, Gentile M, Santoni A, Corda D, Poli G, Ghezzi P, Colotta F. A new class of non-competitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci USA 2004; 101: 11791-11796.
22. Allegretti M, Bertini R, Cesta MC, Bizzarri C, Di Bitondo R, Di Cioccio V, Galliera E, Berdini V, Topai A, Zampella G, Russo V, Di Bello N, Nano G, Nicolini L, Locati M, Fantucci P, Florio S, Colotta F. 2-Arylpropionic CXC Chemokine Receptor 1 (CXCR1) Ligands as Novel Noncompetitive CXCL8 Inhibitors. J Med Chem 2005; 48: 4312-4331.
23. Branduardi P, Sauer M, De Gioia L, Zampella G, Valli M, Mattanovich D, Porro D. Lactate production yield from engineered yeasts is dependent from the host background, the lactate dehydrogenase source and the lactate export. Microb Cell Fact 2006; 5: 4.
24. Moro G, Bonati L, Bruschi M, Cosentino U, De Gioia L, Fantucci P, Pandini A, Papaleo E, Pitea D, Saracino G, Zampella G. Computational approaches to shed light on molecular mechanisms in biological processes. Theor Chem Acc 2007; 117: 723-741.
25. Cipolla L, Redaelli C, Granucci F, Zampella G, Zaza A, Chisci R, Nicotra F. Straightforward synthesis of novel Akt inhibitors based on a glucose scaffold. Carbohydr Res 2010; 345: 1291-1298.
26. Geldenhuys WJ, Nakamura H. 3D-QSAR and docking studies on transforming growth factor (TGF)-β receptor 1 antagonists. Bioorg Med Chem Lett 2010; 20: 1918-1923.
27. Halgren TA, Nachbar RB. Merck molecular force field. IV. Conformational energies and geometries. J Comput Chem 1996; 17: 587-615.
28. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
29. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.
30. Warren L. The thiobarbituric acid assay of sialic acid. J Biol Chem 1963; 234: 1971-1975.
31. Buschiazzo A, Alzari PM. Structural insights into sialic acid enzymology. Curr Opin Chem Biol 2008; 12: 565-572.
32. Magesh S, Suzuki T, Miyagi T, Ishida H, Kiso M. Homology modeling of human sialidase enzymes NEU1, NEU3 and NEU4 based on the crystal structure of NEU2: Hints for the design of selective NEU3 inhibitors. J Mol Graph Model 2006; 25: 196-207.
33. Magesh S, Moriya S, Suzuki T, Miyagi T, Ishida H, Kiso M. Design, synthesis, and biological evaluation of human sialidase inhibitors. Part 1: Selective inhibitors of lysosomal sialidase (NEU1). Bioorg Med Chem Lett 2008; 18: 532-537.
34. Magesh S, Savita V, Moriya S, Suzuki T, Miyagi T, Ishida H, Kiso M. Human sialidase inhibitors: design, synthesis, and biological evaluation of 4-acetamido-5-acylamido-2-fluoro benzoic acids. Bioorg Med Chem 2009; 17: 4595-4603.
35. Monti E, Preti A, Venerando B, Borsani G. Recent development in mammalian sialidase molecular biology. Neurochem Res 2002; 27: 649-663.
36. Albohy A, Li MD, Zheng RB, Zou C, Cairo CW. Insight into substrate recognition and catalysis by the human neuraminidase 3 (NEU3) through molecular modeling and site-directed mutagenesis. Glycobiology 2010; 20: 1127-1138.
37. Wang Y, Yamaguchi K, Shimada Y, Zhao X, Miyagi T. Site-directed mutagenesis of human membrane-associated ganglioside sialidase: identification of amino-acid residues contributing to substrate specificity. Eur J Biochem 2001; 268: 2201-2208.
38. Crennell SJ, Garman EF, Laver WG, Vimr ER, Taylor GL. Crystal structure of a bacterial sialidase (from Salmonella typhimurium LT2) shows the same fold as an influenza virus neuraminidase. Proc Natl Acad Sci USA 1993; 90: 9852-9856.